You have 9 free searches left this month | for more free features.

TKI

Showing 1 - 25 of 1,196

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Nintedanib, gefitinib, erlotinib, afatinib
  • (no location specified)
Oct 2, 2023

Metabolic Alternation and Clinicohematological Characteristic in

Not yet recruiting
  • CML, Chronic Phase
  • Tyrosine kinase inhibitor
  • (no location specified)
Nov 6, 2023

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

IASLC Grading System as a Predictor for EGFR-TKI Therapy

Completed
  • Lung Cancer
  • IASLC grading system
  • Shanghai, Please Select, China
    Chaoqiang Deng
Nov 9, 2023

Non-proliferative Diabetic Retinopathy Trial (OTX-TKI, Sham)

Not yet recruiting
  • Non-proliferative Diabetic Retinopathy
  • (no location specified)
Jan 12, 2023

Chronic Myeloid Leukemia Trial in Jena (Venetoclax)

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Jena, Germany
    Universitätsklinikum Jena
Jan 17, 2023

Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant

Completed
  • The Primary Study Metric is Progression-free Survival (PFS)
    • (no location specified)
    Jun 28, 2023

    Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

    Recruiting
    • Liver Neoplasms
    • Tislelizumab plus tyrosine kinase inhibitor
    • Beijing, Beijing, China
      302 Hospital
    Sep 22, 2023

    Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

    Recruiting
    • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
    • Topical Timolol
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Nov 14, 2023

    NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • HS-10241+ Almonertinib
    • Pemetrexed + Cisplatin /Carboplatin
    • (no location specified)
    Oct 29, 2023

    NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

    Recruiting
    • NSCLC
    • EGFR Gene Mutation
    • neo-antigen vaccine
    • Nanjing, China
      The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
    Oct 19, 2023

    HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy Trial (Trastuzumab Emtansine for Injection, Pyrotinib Maleate

    Not yet recruiting
    • HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
    • Trastuzumab Emtansine for Injection
    • Pyrotinib Maleate Tablets
    • (no location specified)
    Sep 30, 2022

    NSCLC Trial in Singapore (Afatinib 40 MG)

    Not yet recruiting
    • NSCLC
    • Afatinib 40 MG
    • Singapore, Singapore
      National University Hospital
    Sep 25, 2023

    Gastrointestinal Stromal Tumors Trial in Changsha (Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib)

    Recruiting
    • Gastrointestinal Stromal Tumors
    • Apatinib Mesylate
    • Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
    • Changsha, Hunan, China
      Xiangya Hospital, Central South University
    Mar 1, 2023

    EGFR Mutant Advanced NSCLC Trial (BBT-207)

    Not yet recruiting
    • EGFR Mutant Advanced Non-Small Cell Lung Cancer
    • (no location specified)
    Jun 16, 2023

    Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)

    Not yet recruiting
    • Tyrosine Kinase Inhibitors
    • Chronic Myeloid Leukemia
    • treatment of TKI in CML
    • Poitiers, France
      Chu Poitiers
    Feb 21, 2023

    Dalpiciclib Combined With Third-generation EGFR-TKI in EGFR

    Not yet recruiting
    • Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
    • +6 more
      • (no location specified)
      Aug 9, 2022

      Oligometastatic Disease, NSCLC, Driver Mutation Trial in Mumbai (Local Consolidative Radiation Therapy, TKI)

      Recruiting
      • Oligometastatic Disease
      • +2 more
      • Local Consolidative Radiation Therapy
      • TKI
      • Mumbai, Maharashtra, India
        Tata Memorial Hospital
      Mar 11, 2022

      Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)

      Recruiting
      • Non-small-cell Lung Carcinoma
      • Beijing, China
        Cancer Hospital, Chinese Academy of Medical Sciences
      May 11, 2023

      EGFR, NSCLC, Third-generation TKI Trial (Almonertinib and metronomic oral vinorelbine)

      Not yet recruiting
      • EGFR
      • +2 more
      • Almonertinib and metronomic oral vinorelbine
      • (no location specified)
      Dec 21, 2022

      NSCLC Trial (Lazertinib group)

      Not yet recruiting
      • NSCLC
      • Lazertinib group
      • (no location specified)
      Jul 14, 2022

      NSCLC Trial in Chendu (Almonertinib)

      Recruiting
      • Non-small Cell Lung Cancer
      • Chendu, Sichuan, China
        West China Hospital,Sichuan University
      Dec 14, 2022

      Condition Vasoregulation Function Endothelium in CML Getting TKI

      Recruiting
      • Chronic Myeloid Leukaemia
      • taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
      • Moscow, Russian Federation
      • +1 more
      Jan 11, 2023

      Advanced NSCLC Trial (VIC-1911, Osimertinib Mesylate Tablets)

      Not yet recruiting
      • Advanced Non-small Cell Lung Cancer
      • (no location specified)
      Aug 3, 2022

      A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

      Recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • +4 more
        • Guangzhou, Guangdong, China
          Cancer Center, Sun Yat-sen University
        Oct 25, 2022